Stockscreener 앱 받기
47.47
0.88%
-0.42
시장 영업 전:
46.80
-0.67
-1.41%
Sanofi Adr 주식(SNY)의 최신 뉴스
Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week? - Finviz
FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks - Benzinga
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes - Finviz
Sanofi (SNY) Reports Regulatory Win, Barclays Downgrades to 'Equal Weight' with EUR 85 PT - Finviz
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Regeneron Just Moved From Underperform To Buy - Benzinga
KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? - Finviz
Flu Season's Here-This Dividend-Payer Controls the Shot Market - Finviz
FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children - Finviz
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026? - Finviz
Drugmakers Plan Fresh Price Hikes On 350 Medicines In 2026 - Sahm
Jefferies Maintains Buy on Sanofi (SNY) Despite Regulatory Overhang - Finviz
Where is Sanofi (SNY) Headed According to Wall Street? - Finviz
Delayed MS Decision and Trial Miss Add to Sanofi's R&D Challenges - Finviz
Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX) - Finviz
Total debt per share of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView — Track All Markets
Why Dynavax Stock Soared Today - Finviz
Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise - Finviz
Sanofi Makes $2.2 Billion Bet On Adult Vaccines With Dynavax Buy - Sahm
Our Environmental Impact - Sanofi
Bloom Energy Aktie: KI-Boom trifft auf Energiekrise! - Finanztrends
Sanofi (SNY) Shares Under Pressure After JPMorgan and Guggenheim Downgrades - Finviz
FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock? - Finviz
Sanofi (SNY) sees slight pessimism from analysts - MSN
Sanofi: Today's Tolebrutinib Setback Shouldn't Worry ShareholdersThis Is Why (SNY) - Seeking Alpha
Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease Collaboration - Sahm
Sanofi's Multiple Sclerosis Drug Faces Trial And Regulatory Setbacks - Sahm
Sanofi Stock (SAN.PA, SNY) Slides After Tolebrutinib Double Setback: FDA Delay, Trial Miss, and Fresh Analyst Forecasts (Dec. 15, 2025) - ts2.tech
SNY Stock Price and Chart — NASDAQ:SNY - TradingView — Track All Markets
Sanofi (SNY) Sees Slight Pessimism From Analysts - Finviz
JPMorgan Downgrades Sanofi (SNY) to EUR 95 from EUR 105 - Finviz
TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia - Finviz
Why Wall Street Analysts Are Closely Watching Sanofi (SNY) - Finviz
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play - Finviz
KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study - Finviz
Drugmakers Briefed As Vaccine Skeptics Like RFK Jr. Probe RSV Therapy Risks - Sahm
REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock? - Finviz
0.70%
1.21%
자본화:
|
볼륨(24시간):